Graham Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Graham Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$576K	Buy	92,277 +74,618	+423%	+$322K	0.01%	663
2026 Q1	$50K	Buy	+17,659	New	+$59.9K	﹤0.01%	1091
2024 Q3	–	Sell	-71,038	Closed	-$509K	–	1246
2024 Q2	$509K	Buy	+71,038	New	+$613K	0.01%	587
2022 Q3	–	Sell	-25,975	Closed	-$737K	–	1217
2022 Q2	$737K	Sell	25,975 -25,964	-50%	-$822K	0.03%	534
2022 Q1	$1.83M	Buy	51,939 +44,026	+556%	+$1.48M	0.06%	148
2021 Q4	$331K	Buy	+7,913	New	+$321K	0.01%	286

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Graham Capital Management's MRVI Position: Q2 2026 in Review

Graham Capital Management increased its Maravai LifeSciences (MRVI) stake by 423% in Q2 2026, buying an estimated $322K and bringing the position to 92,277 shares worth $576K. The position accounts for 0.01% of the portfolio, ranked #663.

Graham Capital Management first reported a position in MRVI in Q4 2021 and has held it in 6 quarters since. The position peaked at $1.83M in Q1 2022. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Graham Capital Management held 92,277 shares of Maravai LifeSciences worth $576K as of Q2 2026.
Graham Capital Management bought 74,618 Maravai LifeSciences shares in Q2 2026, an estimated $322K.
Maravai LifeSciences made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #663 holding.
Graham Capital Management first reported a position in Maravai LifeSciences in Q4 2021 and has held it in 6 quarters since.
Graham Capital Management's Maravai LifeSciences position peaked at $1.83M in Q1 2022.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.